Monday, April 27, 2026 7:45:13 PM
Investor — you didn’t rebut anything I wrote. You sidestepped the market-structure argument and went straight back to the same, tired LP/dilution/bag-holder narrative. That’s not a counterpoint, it’s a weak, multi-thronged pivot to baffle the unsuspecting with bullshit.
My point was simple: A squeeze only happens when dealers are forced to close. Nothing in 2021–2022 created a forced unwind. So, the absence of a squeeze tells you zero about synthetic exposure — it only tells you there was no trigger. That is simple mechanics and not about LP providing optimism to fleece her investors.
Regarding your statement, "count[ing] on LP to give them plenty of opportunities" [i.e., dilutions], does not address the issue as to whether NWBO's offered shares entered the lending pool. NWBO’s microstructure (thin books, low borrow, MM dominance) shows the borrowable float barely expanded. If dilution had fixed that, the tape would look very different.
And the “there will never be a catalyst” line isn’t a rebuttal — it’s just your prediction that the company fails before any forced-closure event (approval, partnerships, indication expansion, etc.) ever matters. That’s your thesis, not evidence against synthetic exposure or borrow scarcity. It’s also inconsistent with the regulatory reforms underway in both the UK and US (even before NWBO has PR’d a BLA). And your position implies something you know isn’t true — that Wall Street can pile up unlimited short or synthetic exposure forever with no risk, no margin pressure, and no eventual unwind. That’s not how the system works, and you know it.
If you want to challenge the argument, do it... without the misdirection/pivots. Or continue with your agenda.
My point was simple: A squeeze only happens when dealers are forced to close. Nothing in 2021–2022 created a forced unwind. So, the absence of a squeeze tells you zero about synthetic exposure — it only tells you there was no trigger. That is simple mechanics and not about LP providing optimism to fleece her investors.
Regarding your statement, "count[ing] on LP to give them plenty of opportunities" [i.e., dilutions], does not address the issue as to whether NWBO's offered shares entered the lending pool. NWBO’s microstructure (thin books, low borrow, MM dominance) shows the borrowable float barely expanded. If dilution had fixed that, the tape would look very different.
And the “there will never be a catalyst” line isn’t a rebuttal — it’s just your prediction that the company fails before any forced-closure event (approval, partnerships, indication expansion, etc.) ever matters. That’s your thesis, not evidence against synthetic exposure or borrow scarcity. It’s also inconsistent with the regulatory reforms underway in both the UK and US (even before NWBO has PR’d a BLA). And your position implies something you know isn’t true — that Wall Street can pile up unlimited short or synthetic exposure forever with no risk, no margin pressure, and no eventual unwind. That’s not how the system works, and you know it.
If you want to challenge the argument, do it... without the misdirection/pivots. Or continue with your agenda.
"Against stupidity, we are defenseless"-- Dietrich Bonhoeffer, an anti-Nazi German Theologian, executed in the final days of the Nazi regime.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
